Success Metrics

Clinical Success Rate
86.7%

Based on 235 completed trials

Completion Rate
87%(235/271)
Active Trials
24(7%)
Results Posted
36%(85 trials)
Terminated
36(11%)

Phase Distribution

Ph phase_1
60
18%
Ph early_phase_1
7
2%
Ph phase_4
24
7%
Ph phase_3
57
17%
Ph not_applicable
78
23%
Ph phase_2
111
33%

Phase Distribution

67

Early Stage

111

Mid Stage

81

Late Stage

Phase Distribution337 total trials
Early Phase 1First-in-human
7(2.1%)
Phase 1Safety & dosage
60(17.8%)
Phase 2Efficacy & side effects
111(32.9%)
Phase 3Large-scale testing
57(16.9%)
Phase 4Post-market surveillance
24(7.1%)
N/ANon-phased studies
78(23.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.0%

235 of 283 finished

Non-Completion Rate

17.0%

48 ended early

Currently Active

24

trials recruiting

Total Trials

337

all time

Status Distribution
Active(38)
Completed(235)
Terminated(48)
Other(16)

Detailed Status

Completed235
Terminated36
Recruiting18
unknown16
Withdrawn12
Not yet recruiting11

Development Timeline

Analytics

Development Status

Total Trials
337
Active
24
Success Rate
86.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 17 (2.1%)
Phase 160 (17.8%)
Phase 2111 (32.9%)
Phase 357 (16.9%)
Phase 424 (7.1%)
N/A78 (23.1%)

Trials by Status

unknown165%
terminated3611%
withdrawn124%
not_yet_recruiting113%
active_not_recruiting62%
recruiting185%
enrolling_by_invitation31%
completed23570%

Recent Activity

Clinical Trials (337)

Showing 20 of 337 trialsScroll for more
NCT06595238Phase 2

A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

Completed
NCT07848477Not Applicable

PROMOTE: Effects of 5-HT4 Agonism on Cognition and Sleep in Peopl With Low Mood

Not Yet Recruiting
NCT04874012Phase 2

Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes

Recruiting
NCT01336686Phase 2

Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout

Completed
NCT06967259Phase 1

ENA-001 for Opioid Induced Respiratory Depression

Completed
NCT07809321Not Applicable

Beta-Alanine Effects on Neuromuscular and Cardiovascular Performance in Female Rugby Players

Enrolling By Invitation
NCT07746115Not Applicable

Testing Two Doses of Nebulized Ketamine for Postoperative Sore Throat

Completed
NCT06671938Phase 2

Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy

Completed
NCT07637071Not Applicable

Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia

Not Yet Recruiting
NCT07767669Not Applicable

A Controlled Study to Evaluate the Effects of a Topical Cream on Symptoms of Arthritis, Joint, and Muscle Pain

Completed
NCT04627922Phase 4

N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use

Completed
NCT07755735Not Applicable

A Study to Evaluate the Effects of a Fiber Supplement on Gut Health

Completed
NCT05232279Phase 3

Effect of Testofen on Erectile Function in an Adult Male Population

Active Not Recruiting
NCT06601218Phase 1

Impact of Daily Oral Cannabis Doses in Patients With Cancer

Recruiting
NCT06641466Phase 3

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Recruiting
NCT03781115Phase 1

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

Active Not Recruiting
NCT06472791Not Applicable

Centella Asiatica in Older Adults

Completed
NCT07264517Phase 2

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

Completed
NCT06684379Phase 1

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

Recruiting
NCT01224795Phase 3

A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
337